Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc (CDIO) delivers AI-powered innovations in cardiovascular risk assessment through its proprietary Genetic-Epigenetic Engine. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's advancements in precision diagnostics.
Access timely announcements about clinical validations, strategic partnerships, and regulatory developments shaping the future of preventive cardiovascular care. Our curated collection includes earnings reports, technology milestones, and peer-reviewed research insights directly impacting CDIO's market position.
Key updates cover advancements in AI-driven diagnostic accuracy, intellectual property expansions, and collaborations with medical institutions. Users gain critical insights into how CDIO's epigenetic analyses are transforming personalized healthcare approaches globally.
Bookmark this page for structured access to verified corporate communications and analysis of CDIO's growing influence in biotechnology. Regularly updated content supports informed tracking of the company's progress in redefining cardiovascular disease prevention through cutting-edge diagnostic solutions.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) has announced its sponsorship of the Becker’s Hospital Review 13th Annual Meeting from April 3-6, 2023, in Chicago. The event will showcase the company’s new test, PrecisionCHD, at booth #300. This annual meeting will gather over 420 hospital and health system executives to discuss critical healthcare issues. The company focuses on improving cardiovascular disease detection and treatment through its proprietary Integrated Genetic-Epigenetic Engine. CEO Meesha Dogan emphasized the opportunity to showcase innovations aimed at enhancing patient care and reducing costs.
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has entered a securities purchase agreement with YA II PN, Ltd., securing up to $11.2 million through convertible debentures. The initial closing provided $4.5 million, with plans to utilize the funds for accelerating the adoption of its PrecisionCHD and Epi+Gen CHD clinical tests and developing additional cardiovascular disease tests. CEO Meesha Dogan emphasized that this financing will enhance the company's mission in heart disease prevention. Northland Capital Markets acted as the sole placement agent.
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announces the appointment of Dr. Damon Broyles as a strategic advisor. With extensive experience in healthcare innovation and precision medicine, Dr. Broyles will guide Cardio Diagnostics in overcoming challenges and seizing opportunities in cardiovascular disease and precision medicine. He currently leads clinical innovation initiatives at Mercy Technology Services and has played a crucial role in advancing Mercy's precision medicine efforts. CEO Meesha Dogan expresses confidence that Dr. Broyles' leadership will enhance growth and value creation for the company.
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) announced a significant development as China's Patent Office issued a Notice of Allowance for their patent application titled 'Compositions and Methods for Detecting Predisposition to Cardiovascular Disease.' This patent is exclusively licensed from the University of Iowa Research Foundation and was co-invented by the company's founders. The Notice signifies that the invention meets the patentability requirements, with the patent already granted in the U.S. and Europe. CEO Meesha Dogan expressed excitement over this milestone, highlighting the company's commitment to enhancing healthcare outcomes through a strong intellectual property portfolio.
Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) has launched PrecisionCHD™, the first integrated epigenetic-genetic blood test aimed at early detection of coronary heart disease (CHD). This test utilizes a proprietary AI-driven engine to enhance sensitivity to over 75% for CHD detection. PrecisionCHD will appeal to clinicians by providing a non-invasive alternative to traditional tests, thus improving accessibility. Following its initial availability for existing customers, a nationwide rollout is expected soon. The test will debut at the American College of Cardiology's annual session from March 4-6, 2023.
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) announces the introduction of its rapidly accessible coronary heart disease test, PrecisionCHD, at the American College of Cardiology’s 72nd Annual Scientific Session in New Orleans, LA, from March 4-6, 2023. This test leverages epigenetics, genetics, and artificial intelligence to enhance early detection of coronary heart disease. The company aims to improve patient experiences with effective and efficient assessments, reducing wait times significantly compared to traditional methods, which often take weeks or months. CEO Meesha Dogan emphasizes the need for advancements in cardiovascular disease detection and treatment.
Cardio Diagnostics Holdings (Nasdaq: CDIO) has partnered with Healing Sanctuary Clinic in Idaho to offer the Epi+Gen CHD Precision Cardiovascular Test. This innovative test leverages epigenetics, genetics, and AI to identify patients at risk for coronary heart disease. The collaboration aims to enhance patient outcomes and reduce heart disease incidence in the U.S. Cardio Diagnostics emphasizes its commitment to making precision diagnostics accessible and effective in heart disease prevention.
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) will attend the JP Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. This significant event gathers healthcare leaders to share insights and innovations. Cardio Diagnostics aims to showcase its advancements in cardiovascular disease prevention and detection, connecting with strategic partners, investors, and analysts. The company is committed to enhancing personalized healthcare through its AI-driven Integrated Genetic-Epigenetic Engine, striving to become a key player in medical technology.
Cardio Diagnostics Holdings Inc (Nasdaq: CDIO) has partnered with Houston Concierge Medicine to offer the Epi+Gen CHD precision cardiovascular disease test, targeting executives in Houston, Texas. This test utilizes epigenetics and AI to identify coronary heart disease risks, enhancing preventive care for high-stress professionals. The collaboration highlights a growing trend of executive physicals aimed at long-term health benefits, potentially reducing future medical costs and absenteeism. The Houston practice emphasizes its commitment to best-in-class diagnostic solutions, addressing heart health concerns among its clientele.
Cardio Diagnostics (Nasdaq: CDIO) has been recognized in Fast Company’s Next Big Things in Tech list, which highlights transformative technology breakthroughs. This year features 83 technological advancements from various sectors, showcasing innovations that could impact businesses and society within five years. The company focuses on cardiovascular disease prevention using integrated epigenetics-genetics and AI. The recognition emphasizes Cardio’s commitment to improving personalized healthcare.
Fast Company’s Winter 2022/2023 issue is available online.
